Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

70.73 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup
Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the stock. 
Via Stocktwits
Topics Law Enforcement Lawsuit
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry. 
Via Benzinga
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
Why Did Hims and Hers Stock Crash on Monday?
Via The Motley Fool
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Via The Motley Fool
Hims & Hers Stock Rebounds After-Hours After Novo Nordisk Split Triggers Record Plunge — Retail Traders Stay Loyal
On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday. 
Via Stocktwits
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically... 
Via Stocktwits
Why Novo Nordisk Stock Is Sinking Today
Via The Motley Fool
Topics Stocks Supply Chain
Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday?
Wall Street resilient as Iran fires missiles at U.S. bases in Qatar and Iraq, defying expectations in energy market. U.S. equities and gold up, bonds down. 
Via Benzinga
Topics Bonds
Hims & Hers Stock Plunges As Novo Nordisk Ends Partnership Over Allegations Of Selling Knockoff Versions Of Wegovy
Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions... 
Via Stocktwits
Topics Law Enforcement
Hims & Hers Health Stock Is Tumbling Monday: What's Happening?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company. 
Via Benzinga
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals. 
Via Benzinga
IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs
Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide. 
Via Investor's Business Daily
Dow Futures Edge Lower As Iran Moves To Block Strait Of Hormuz: Exxon, Chevron, Occidental, Tesla Among Stocks In Focus
Via Stocktwits
Topics Stocks
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation
NOVO-NORDISK (NYSE:NVO) offers strong growth, high profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth stocks. 
Via Chartmill
Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders
Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector. 
Via Stocktwits
Novo Nordisk Gains Ground In Obesity Race As Amycretin, Wegovy Show Significant Weight Loss
The company is advancing amycretin to Phase 3 and pursuing regulatory approval for a higher Wegovy dose. 
Via Stocktwits
5 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
McDonald’s Is Down, But Long-Term Investors Can Still Take a Bite
Analysts are downgrading McDonald's and the stock may have further to fall, but as a long-term opportunity, it may be getting to a point of offering real value 
Via MarketBeat
How Do Investors Really Feel About Novo Nordisk?
Via Benzinga
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
This dark horse candidate has emerged to take significant share in the weight-loss drugs space. 
Via Investor's Business Daily
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors
NOVO-NORDISK A/S (NYSE:NVO) is a strong value stock with high profitability, solid growth, and an attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
Why Scholar Rock Shares Are Soaring Today
Via The Motley Fool
Topics Stocks
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Why Novo Nordisk Stock Sank by Nearly 4% Today
Via The Motley Fool
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic. 
Via Benzinga
Topics Intellectual Property
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.